Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12824361 | 0.84 | ALDH1A1 (0.96) | TDP1ALDH1A1MAPTKCNJ1TP53 | |
| SCHEMBL13711958 | 0.82 | ALDH1A1 (1.00) | TDP1ALDH1A1MAPTKCNJ1TP53 | |
| SCHEMBL12515889 | 0.82 | ALDH1A1 (1.00) | TDP1ALDH1A1MAPTKCNJ1TP53 | |
| SCHEMBL12824499 | 0.81 | ALDH1A1 (0.72) | TDP1ALDH1A1MAPTKCNJ1RAB9A | |
| SCHEMBL1852489 | 0.79 | ALDH1A1 (0.70) | TDP1ALDH1A1MAPTKCNJ1RAB9A | |
| SCHEMBL7231518 | 0.79 | ALDH1A1 (0.70) | TDP1ALDH1A1MAPTKCNJ1RAB9A | |
| SCHEMBL20771270 | 0.79 | TDP1 (0.65) | TDP1ALDH1A1MAPTKCNJ1RAB9A | |
| SCHEMBL2629383 | 0.77 | TDP1 (0.62) | TDP1ALDH1A1MAPTTP53NPSR1 | |
| SCHEMBL1897864 | 0.77 | TDP1 (0.62) | TDP1ALDH1A1MAPTTP53NPSR1 | |
| SCHEMBL12824606 | 0.74 | ALDH1A1 (0.71) | TDP1ALDH1A1MAPTKCNJ1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9815849-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815849-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2012-09-27 | — | — | US | disclosed |
| EP-2488519-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | Pierre Fabre Médicament (FR) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011088201-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011045344-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | PIERRE FABRE MEDICAMENT (FR) | 2011-04-21 | — | — | WO | disclosed |
| US-7910579-B2 | Benzoxazole derivatives | TOHOKU UNIVERSITY (JP) | 2011-03-22 | — | — | US | disclosed |
| EP-2103611-A1 | BENZOXAZOLE DERIVATIVES | Tohoku University (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | TDP1 688/4885ALDH1A1 2424/4885MAPT 1886/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | TDP1 1447/4885ALDH1A1 3670/4885MAPT 2072/4885 |
| US-20120245170-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT | DPYD, TYMP, ABCB1 | TDP1 645/4885ALDH1A1 170/4885MAPT 3678/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | TDP1 2688/4885ALDH1A1 1723/4885MAPT 4443/4885 |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, KCNB2, SCNN1B | TDP1 4635/4885ALDH1A1 2656/4885MAPT 1880/4885 |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | BRDT, BRD4, BRD1 | TDP1 688/4885ALDH1A1 2424/4885MAPT 1886/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | TDP1 2688/4885ALDH1A1 1723/4885MAPT 4443/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | TDP1 1447/4885ALDH1A1 3670/4885MAPT 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.